The significantly higher tumor mutation burden and neoantigen burden were observed in aggregated NSCLC samples with LRP1B mutations by Wilcoxon rank sum test (log2 TMB, 8.3 vs. 7.1, P < 0.001; log2 NB, 8.7 vs. 7.4, P < 0.001) (Figures 5A,B). This evidence concerns the gene LRP1B and non-small cell lung carcinoma.